Synergy Spine Solutions Closes $30 Million Series A Financing

Synergy Spine Solutions has closed $30 million Series A financing led by Amzak Health to complete enrollment of its U.S. IDE 2-level clinical trial, continue patient follow-up on both the 1-level and 2-level clinical trials, submit anticipated Pre-Market Approval applications to the FDA, as well as to support continued commercialization in markets outside the United States.

Synergy remains at the forefront of addressing the critical need for innovative solutions in cervical disc replacement. Enrollment for the Synergy Disc® 1-level IDE trial was recently completed in June 2023.

The 2-Level trial will evaluate the safety and effectiveness of the Synergy Disc® artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of degenerative disc disease in subjects that are symptomatic at two contiguous vertebral levels from C3 to C7. This is a multi-center, prospective, non-randomized, historically controlled study that will be conducted on 200 patients at up to 25 sites.

We remain focused on completing the 2-level study and to bringing the Synergy Disc® to the U.S. market, as it represents an important treatment option for patients suffering from degenerative disc disease and was specifically designed to restore both motion and alignment to the cervical spine,” said Josh Butters, CEO of Synergy Spine Solutions.

To view the source version, please click HERE.

en_GBEnglish (UK)